Admedus Limited
(ASX:AHZ) says its CardioCel technology has won a label expansion in the European market.
The upgrade means the product can now be used in the repair and reconstruction of heart valves as well as in heart defects in a European market estimated to be worth over $1 billion.
The technology is now on market in Canada, the USA, Hong Kong, Singapore and Malaysia as well as Europe and is looking at ways to gain regulatory approval in the Middle East and Northern African markets.
Further clinical studies are underway to lift the clinical data available around whole valve reconstructions.
Admedus made a net loss of $26.8 million for the 2015 financial year.
